

**Pharmacy Policy**

---

# Homozygous Familial Hypercholesterolemia

**Policy Number:** 9.603

**Version Number:** 2

**Version Effective Date:** 3/1/2022

<b>Product Applicability</b> <input type="checkbox"/> <b>All Plan+ Products</b>	
<b>Well Sense Health Plan</b> <input type="checkbox"/> New Hampshire Medicaid	<b>Boston Medical Center HealthNet Plan</b> <input checked="" type="checkbox"/> MassHealth - MCO <input checked="" type="checkbox"/> MassHealth - ACO <input type="checkbox"/> Qualified Health Plans/ConnectorCare/Employer Choice Direct <input type="checkbox"/> Senior Care Options

Note: Disclaimer and audit information is located at the end of this document.

**Prior Authorization Policy**

---

**Products Affected:**

- **Evkeeza (evinacumab-dgnb)**
- **Juxtapid (lomitapide)**

The Plan may authorize coverage of the above products for members meeting the following criteria:

<b>Covered Use</b>	All FDA approved indications not otherwise excluded
<b>Exclusion Criteria</b>	Concurrent use with PCSK9 inhibitors
<b>Required Medical Information</b>	<b>Juxtapid:</b> 1. Documentation of diagnosis of homozygous familial hypercholesterolemia; confirmed by the following (A AND B): a.

\* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

	<ul style="list-style-type: none"> <li> <ul style="list-style-type: none"> <li>i. Genetic testing confirming mutation of two mutant alleles at low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), proproteinconvertase subtilisinexintype 9 (PCSK9), or low-density lipoprotein receptor adaptor protein 1 (LDLRAP1) gene locus; OR</li> <li>ii. If genetic testing was negative or inconclusive: prescriber must provide documentation attesting to a mutation that may cause familial hypercholesterolemia</li> </ul> </li> <li>b. One of the recognized diagnostic criteria are met           <ul style="list-style-type: none"> <li>i. Dutch Lipid Clinic criteria; OR</li> <li>ii. Simon Broome criteria</li> </ul> </li> </ul> <p>2. Documentation of medication being prescribed by, or in written consultation with (documentation required), a lipid specialist (e.g., cardiologist, endocrinologist, lipid specialist); <b>AND</b><u>One</u> of the following:</p> <ul style="list-style-type: none"> <li>a. Inadequate LDL reduction while adherent to a minimum of 90 day continuous use of atorvastatin 80mg or rosuvastatin 40mg in combination with ezetimibe evidenced by:           <ul style="list-style-type: none"> <li>i. Current LDL-C greater than or equal to 100mg/dL; <b>AND</b></li> <li>ii. Less than a 50 percent reduction in LDL-C from baseline; <b>OR</b></li> </ul> </li> <li>b. Inability to tolerate a high intensity statin (atorvastatin 80mg or rosuvastatin 40mg); <b>AND</b> <ul style="list-style-type: none"> <li>i. Inadequate response while adherent to a minimum of 90 day continuous use of a maximum tolerated dose of a non-high intensity statin and ezetimibe evidenced by:               <ul style="list-style-type: none"> <li>1. Current LDL-C greater than or equal to 100mg/dL; <b>AND</b></li> </ul> </li> </ul> </li> </ul> <p>3. An inadequate response to Repatha while adherent to a minimum of 90 day continuous use as evidenced by:</p> <ul style="list-style-type: none"> <li>a. Current LDL-C greater than or equal to 100 mg/dL; <b>OR</b></li> <li>b. An adverse effect or contraindication to Repatha; <b>AND</b></li> </ul> <p>4. Baseline LDL-C level is provided</p> <p><b>Evkeeza:</b></p> <ul style="list-style-type: none"> <li>1. Documentation of medication being prescribed by, or in written consultation with (documentation required), a lipid specialist (e.g., cardiologist, endocrinologist, lipid specialist); <b>AND</b></li> <li>2. Member is greater than or equal to 12 years of age; <b>AND</b></li> <li>3. Baseline LDL-C level is provided; <b>AND</b></li> <li>4. Documentation of confirmed diagnosis of homozygous hypercholesterolemia confirmed by the following (A <b>AND</b> B):           <ul style="list-style-type: none"> <li>a.               <ul style="list-style-type: none"> <li>i. Genetic testing confirming mutation of two mutant alleles at low-density</li> </ul> </li> </ul> </li> </ul>
--	--

\* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.  
Homozygous Familial Hypercholesterolemia

	<p>lipoprotein receptor (LDLR), apolipoprotein B (APOB), proproteinconvertase subtilisin/exin type 9 (PCSK9), or low-density lipoprotein receptor adaptor protein 1 (LDLRAP1) gene locus; OR</p> <p>ii. If genetic testing was negative or inconclusive: prescriber must provide documentation attesting to a mutation that may cause familial hypercholesterolemia</p> <p>b. One of the recognized diagnostic criteria are met</p> <p>i. Dutch Lipid Clinic criteria OR</p> <p>ii. Simon Broome criteria; AND</p> <p>5. Documentation of inadequate response to or contraindication to ALL of the following despite 90 days of compliant therapy:</p> <p>a. One high-intensity statin prescribed at the maximally tolerate dose; AND</p> <p>b. Ezetimibe; AND</p> <p>c. PCSK9 inhibitor; AND</p> <p>6. Attestation that current lipid lowering therapy will be used concurrently; AND</p> <p>7. Attestation of patient lifestyle modifications (e.g. low fat diet, exercise)</p>
<b>Age Restriction</b>	Juxtapid: 18 years and older Evkeeza: 12 years and older
<b>Prescriber Restriction</b>	Prescribed by, or in written consultation with (documentation required), a lipid specialist (e.g., cardiologist, endocrinologist, lipid specialist)
<b>Coverage Duration</b>	Initial: 6 months Reauthorization: 12 months
<b>Other criteria</b>	Re-authorization: <ol style="list-style-type: none"> <li>1. Initial criteria has been met; AND</li> <li>2. Documentation of clinical response to therapy as defined by a decrease in LDL-C levels from baseline; AND</li> <li>3. Member has been compliant with therapy (confirmed by pharmacy claims); AND</li> <li>4. For Juxtapid™: Liver function test including AST and ALT are being monitored every 3 months and will be discontinued if liver function tests are 3 times the ULN.</li> </ol>

## Clinical Background Information and References

1. Rosenson R, de Ferranti S, Durrington P. Treatment of drug resistant hypercholesterolemia. UptoDate. Last updated January 30, 2013, Accessed April 2014. Available from <http://www.uptodate.com>.
2. Rosenson R, de Ferranti S, Durrington P. Inherited disorders of LDL-cholesterol metabolism. UptoDate. Last updated February 12, 2014, Accessed April 2014. Available from <http://www.uptodate.com>.
3. Ito M, McGowan M, Moriarty P. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology. 2011;5: S38-S45.
4. Juxtapid™ [package insert]. Cambridge (MA): Aegerion Pharmaceuticals; March 2016.
5. Evkeeza [package insert]. Tarrytown, NY; Regeneron Pharmaceuticals; February 2021.

\* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

**Applicable Coding:**

J -Code	Medication
J1305	Injection, evinacumab-dgnb, 5 mg

Original Approval Date	Original Effective Date	Policy Owner	Approved by
12/1/2020	1/1/2021	Pharmacy Services	Pharmacy & Therapeutics (P&T) Committee

**Policy Revisions History**

Review Date	Summary of Revisions	Revision Effective Date	Approved by
12/1/2020	9.039 Homozygous FH Policy retired, new policy created	1/1/2021	P&T Committee
11/11/2021	Diagnosis documentation expanded to require genetic testing and diagnostic criteria. Baseline LDL-C level is now required to be provided for initial approval. Age restrictions updated to labeling, provider restriction added. Initial approval set to 6 months. Reauthorization criteria now requires initial criteria to have been met. Criteria for Evkeeza added to policy along with Jcode	3/1/2022	P&T Committee

**Next Review Date**

11/2022

**Other Applicable Policies****Reference to Applicable Laws and Regulations, If Any****Disclaimer Information**

Medical Policies are the Plan's guidelines for determining the medical necessity of certain services or supplies for purposes of determining coverage. These Policies may also describe when a service or supply is considered experimental or investigational, or cosmetic. In making coverage decisions, the Plan uses these guidelines and other

\* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

Plan Policies, as well as the Member's benefit document, and when appropriate, coordinates with the Member's health care Providers to consider the individual Member's health care needs.

Plan Policies are developed in accordance with applicable state and federal laws and regulations, and accrediting organization standards (including NCQA). Medical Policies are also developed, as appropriate, with consideration of the medical necessity definitions in various Plan products, review of current literature, consultation with practicing Providers in the Plan's service area who are medical experts in the particular field, and adherence to FDA and other government agency policies. Applicable state or federal mandates, as well as the Member's benefit document, take precedence over these guidelines. Policies are reviewed and updated on an annual basis, or more frequently as needed. Treating providers are solely responsible for the medical advice and treatment of Members.

The use of this Policy is neither a guarantee of payment nor a final prediction of how a specific claim(s) will be adjudicated. Reimbursement is based on many factors, including member eligibility and benefits on the date of service; medical necessity; utilization management guidelines (when applicable); coordination of benefits; adherence with applicable Plan policies and procedures; clinical coding criteria; claim editing logic; and the applicable Plan – Provider agreement.

\* *Plan* refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.